Abstract | As Nature Reviews Immunology reaches its 10 th anniversary, the authors of one of the top-cited articles from each year take a trip down memory lane. We've asked them to look back on the state of research at the time their Review was published, to consider why the article has had the impact it has and to discuss the future directions of their field. This Viewpoint article provides an interesting snapshot of some of the fundamental advances in immunology over the past 10 years. Highlights include our improved understanding of Toll-like receptor signalling, and of immune regulation mediated by regulatory T cells, indoleamine 2,3-dioxygenase, myeloid-derived suppressor cells and interleukin-10. The complexities in the development and heterogeneity of macrophages, dendritic cells and T helper cells continue to engage immunologists, as do the immune processes involved in diseases such as atherosclerosis. We look forward to what the next 10 years of immunology research may bring. PERSPECTIVES NATURE REVIEWS | IMMUNOLOGY VOLUME 11 | OCTOBER 2011 | 693
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, the TLR field was just starting to explode, with numerous discoveries being reported on a monthly basis. It was already becoming clear that TLRs are the most potent inducers of the inflammatory response, that most microbial preparations or purified molecules with immunostimulatory activities are sensed by TLRs, and that TLR ligands are potent activators of dendritic cell (DC) maturation. In addition, TLRs provided the first clear example that pattern recognition receptors of the innate immune system can control the activation of adaptive immune responses. These early studies also revealed that TLRs control some, but not all, adaptive immune responses, indicating that additional pathways must exist.
Since these early days of TLR biology, much progress has been made in the field. The specificities of most TLRs for their microbial ligands have been elucidated. The first few structures of TLRs complexed with their ligands have provided spectacular insights into the mechanisms of pattern recognition. They revealed how the shared molecular patterns of conserved bacterial lipids are recognized by TLRs, either directly, or through the accessory protein MD2. Completely unexpectedly, TLR7 and TLR9 were found to undergo proteolytic processing in their ectodomain to become competent for ligand recognition. These findings were surprising, as they indicated that large portions of the ectodomains of these TLRs are dispensable for ligand binding.
Although major components of the signalling pathways downstream of TLRs have been fairly well characterized, the exact mechanisms by which TLRs induce gene expression remain largely unknown. Indeed, these signalling pathways have turned out to be far more complex than was expected 10 years ago (FIG. 1) and to involve a high degree of cross-regulation that is only starting to be elucidated. Particularly fascinating are the cell biological themes that recur in TLR signalling. For example, TLRs have been found to induce distinct signalling pathways from different cellular compartments, highlighting the role of TLR trafficking in signal transduction. Equally exciting are in vivo findings that implicate TLRs in the initiation of sterile inflammation. Here, TLRs may play a protective role by orchestrating tissue repair, but this very function may also contribute to tumorigenesis and other pathologies.
The role of TLRs in pathogen recognition is now well documented, although it is not yet fully understood. Some questions that existed in the TLR field 10 years ago remain unanswered or, at best, poorly characterized. For example, what is the full spectrum of endogenous TLR ligands? Do endogenous TLR ligands elicit the same responses as pathogen-derived ligands? What is the biological significance of sterile inflammation induced by endogenous TLR ligands? What are the functions of TLRs outside of the immune system and host defence? Several examples that implicate TLRs in the control of metabolism and tissue repair are known, but the mechanisms involved are not yet defined. Do TLRs distinguish between commensal and pathogenic microorganisms and, if so, how? How do TLRs functionally interact with other pattern recognition receptors, such as retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and the dectin family of lectin-like receptors? Several new families of receptors involved in pathogen recognition have been characterized over the past few years, and several more types of innate immune sensor probably exist that have yet to be described. Given that these receptor families have very different properties, it would be interesting V I E W P O I N T κ κ κ κ Figure 1 | Toll signalling pathways. The Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R)-family members share several signalling components, including the adaptor MyD88, Toll-interacting protein (TOLLIP), the protein kinase IRAK (IL-1R-associated kinase) and TRAF6 (TNF receptor-associated factor 6). TRAF6 can activate nuclear factor-κB (NF-κB) through TAK1 (TGF-β-activated kinase), and JNK (c-Jun N-terminal kinase) and p38 MAP kinases through MKK6 (mitogen-activated protein kinase kinase 6). TLR4 signals through another adaptor in addition to MyD88-TIRAP (Toll/interleukin-1 (IL-1) receptor domain-containing adaptor protein), which activates MyD88-independent signalling downstream of TLR4. to determine in future studies whether they have equivalent and autonomous roles in host defence, or whether they have to operate in specific combinations.
Fashions in science come and go. The most important discoveries, however, are made before and after the subject is in fashion. Perhaps TLRs still keep some of their best secrets. 17, 18 . The IL-23 heterodimer shares the p40 chain and a receptor chain with IL-12, whereas the IL-27 heterodimer has structural and sequence homologies with IL-12 but no shared components. Initially, it was thought that IL-23 and IL-27 had partially overlapping functions with IL-12, but the discovery that most of the inhibitory effect of IL-12p40-specific antibodies on autoimmunity was due to their ability to inhibit IL-23 dramatically revolutionized the field 19, 20 . IL-23 was found to be one of the important factors for inducing and maintaining a T H 17 cell response, and the role of T H 1 and T H 17 cells in mediating autoimmunity was re-evaluated 20, 21 . At the same time, the immune-activating functions of IL-27 had been re-evaluated, and the important role of IL-27 in the downregulation of T cell responses (particularly those of T H 1 and T H 17 cells) and in the induction of IL-10 production by T cells was fully appreciated 21 .
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Given that my 2003
Review appeared at such a critical junction in the study of T cell immunity, and therefore at a time of renewed interest in this family of immune regulatory cytokines, it is of no surprise that it was highly read and cited. , three key questions were unresolved: one, the role of IDO in immune regulation and the therapeutic potential of manipulating IDO activity; two, the origin and biological significance of 'IDO-competent DCs'; and three, the molecular mechanisms that explained IDO-mediated regulation of immunity.
Substantial progress on all three issues has been made in the last 7 years. IDO has been shown to control local innate immunity (inflammation) and to regulate antigen-specific adaptive immune responses in settings as diverse as mucosal tolerance, asthma, acquired tolerance to allografts, chronic infection and tumour-induced immunosuppression. In the case of cancer, numerous studies have identified IDO expression in patients with malignancy. Treating tumour-bearing mice with IDO inhibitors enhances tumour-specific immunity and synergizes with cytotoxic chemotherapy to improve treatment of established tumours 23, 24 , and IDO inhibitors have recently entered Phase II oncology trials.
In infectious disease, the classical view that IDO inhibits pathogen replication appears to apply in some settings. In other settings, pathogen-induced IDO may attenuate host T cell immune responses and facilitate the persistence of certain infections, such as HIV and tuberculosis 25, 26 . Thus, depending on the pathogen, IDO may help or hinder antimicrobial immune responses, and this is an active area of research 27 . IDO expression is also a common feature of autoimmune, allergic and graft-versus-host diseases, and in these settings IDO inhibition markedly exacerbates disease severity.
In the case of transplantation, David Wilkes and colleagues 28 first showed that IDO gene transfer protected lung allografts, and similar approaches have been used to protect pancreatic islet, skin and corneal allografts. Of note, overexpression of IDO in transplanted lungs profoundly impairs the cytotoxic functions of host T cells that infiltrate the allografts 29 . Therefore, the common theme that permeates all of these studies is that IDO helps to establish acquired immunological unresponsiveness at sites of inflammation.
At the molecular level, IDO has been shown to promote immune regulation in two ways. First, it depletes tryptophan, and this activates the cellular stress response pathway via the kinase GCN2 (also known as EIF2AK4) 30 ; and, second, it produces kynurenine metabolites, which bind to the aryl hydrocarbon receptor 31 . IDO can be induced by pro-inflammatory cytokines or by a 'reverse signalling' pathway via the interaction of CD80 and CD86 on DCs with cytotoxic T lymphocyte antigen 4 (CTLA4) expressed by T Reg cells 32 . 33, 34 . IDO also appears to stabilize the regulatory phenotype of T Reg cells and prevent T Reg cell reprogramming into helper-like T cells 33 . Thus, IDO continues to emerge as a pivotal molecule in acquired immunological unresponsiveness that occurs at sites of inflammation in settings of clinical significance.
2005 Macrophage heterogeneity: are we (still) missing the point? Siamon Gordon. The heterogeneity of monocytes, macrophages and closely related DCs and osteoclasts has been a recurring theme in the study of these specialized myeloid-derived phagocytes. They are found in haematopoietic compartments and the circulation, and are also present in large numbers in tissues, even in the absence of inflammation. They have a bewildering diversity of phenotype, a feature of both opportunity and frustration for immunologists. Earlier discussions of nomenclature gave rise to terms such as the reticuloendothelial system and mononuclear phagocyte system. But it wasn't until the advent of monoclonal antibodies specific for glycoproteins that appear to be restricted to these cell types (including F4/80 and CD68) that tissue variation in the morphology of macrophages (for example, in the liver, skin and brain) could be correlated with differences in the expression of these molecules 35 . Cells of this unitary lineage can be identified during development and, in adults, they occur in haematopoietic organs, in the blood (as monocytes) and in tissues (constitutively as resident macrophages and also as recruited inflammatory cells). However, it was difficult to distinguish between their differentiation, maturation and modulation (activation and deactivation). The neglected topic of population dynamics and precursorproduct relationships was transformed by the study of Geissmann and Jung 36 using CX 3 Cchemokine receptor 1 (CX 3 CR1; also known as fractalkine receptor)-transgenic mice, which showed that monocyte subsets exist in mice and also provided an experimental tool to confirm and extend earlier studies by Ziegler-Heitbrock 37 on human monocytes. Our Review in Nature Reviews Immunology 38 was therefore opportune and timely, but only the beginning of an ongoing flow of reviews on this subject. The topic continues to provoke controversy, as is evident from a recent attempt to clarify issues, and a consensus has not been reached among several investigators 39 . Terms such as plasticity and polarization, and the socalled M1 and M2 phenotypes, are poorly defined and incompletely understood, especially as microarray and proteomic analyses accumulate.
Anniversaries -30 years for F4/80 and 10 years for Nature Reviews Immunology -provide an opportunity to assess where we are now, as a pointer to the future. My personal view is that, as a field, we are to a great extent still missing the point. In order to understand the extent and significance of monocyte and macrophage heterogeneity we need to investigate the population dynamics and individual cell functions of the bulk of macrophages within the different compartments of the body in situ. Macrophages embedded in tissues are often difficult to isolate and the cells rapidly lose their special features once removed from their native microenvironment. Fluorescence-activated cell sorting (FACS) analysis is biased by ease of isolation; immunocytochemistry is qualitative; and in situ hybridization is cumbersome, as is laser capture microscopy. Intravital microscopy and transgenesis offer further experimental opportunities.
Macrophages are found in the absence of disease in all organs, but we know very little about the role of these cells in sites such as the brain (where they are termed microglia), gut, lung and elsewhere. Although monocytes and macrophages that are recruited during inflammation are better characterized than resident macrophages, there is still considerable ignorance regarding their origin, distribution, longevity and modulation by immune and non-immune stimuli. This applies to their complex roles in promoting or counteracting many disease processes, including infections (for example, tuberculosis, HIV/AIDS and malaria), as well as their roles in modified inflammatory pathologies such as malignancy, atherosclerosis and Alzheimer's disease.
Through their array of surface and intracellular receptors, monocytes and macrophages adapt readily to their microenvironment. Their versatile gene expression, protein synthesis and secretory capacity are legendary. It seems invidious to select only immune complexes 40 or a limited number of cytokines (such as IFNγ, IL-4, IL-13 and IL-10) 41, 42 among many stimuli as inducers of characteristic signatures of gene expression and as regulators of macrophage functional diversity. Expression and activation of macrophage transcription factors, as well as epigenetic and translational controls, are still poorly defined.
Although the influence of T cells on immunity is undoubted, macrophage heterogeneity is still apparent in T cell-deficient hosts, and antigen-presenting cells may themselves determine T cell heterogeneity. Above all, our knowledge of human tissue macrophage heterogeneity is surprisingly limited, even in the case of major haematopoietic organs (such as the spleen), where the heterogeneity is different to that in rodent models. As information from systems biology floods in, we will require new technologies to dissect the functional relevance of macrophage heterogeneity in vivo by non-invasive and invasive methods. The identification of new pathways, mechanisms and targets will then make functionally hetero geneous macrophage subpopulations amenable to selective therapeutic manipulation. 43 . We highlighted the evidence supporting a pro-atherogenic role for T H 1 cells and their signature cytokines, versus a possible mitigating role for a T H 2-polarized immune response and for T Reg cells (and, hence, transforming growth factor-β (TGFβ)), and a putative protective effect of humoral immunity. This postulated tug-ofwar between different arms of the innate and adaptive immune systems generally has withstood the test of time (FIG. 2) . However, new data have challenged some previously prevalent notions of the stimuli for the adaptive immune response during atherogenesis. The conventional DCs (cDCs) in the spleen of steady-state mice derive from an intrasplenic precursor, a pre-cDC. This precursor population might be replenished from earlier precursor cells that are generated in the bone marrow, which might occasionally seed the spleen from the bloodstream. Alternatively, as the spleen remains a haematopoietic organ in mice, the pre-cDCs might be generated endogenously. A late branch in the cDC developmental pathway, detected by high or low expression of CD24 on the precursor cells, leads to pre-cDCs in the spleen that are pre-committed to form either CD8 + or CD8 -cDCs, respectively. The cDCs so formed are in an immature state and are still capable of some homeostatic proliferation. In contrast to the cDCs, the plasmacytoid DCs (pDCs) are generated in the bone marrow by a pathway that branches off from that of cDCs. The pDCs found in the mouse spleen and other tissues probably arrive there from the bloodstream. This steady-state situation changes after microbial stimulation or inflammation. In addition to full activation of the resident cDCs and the pDCs in the spleen, a new type of 'inflammatory DC' is then generated from monocytes, a DC type that is not present in the steady state. GM-CSF, granulocyte/ macrophage colony-stimulating factor. Image is reproduced, with permission, from In particular, recent findings suggest that native low-density lipoprotein (LDL), rather than oxidized LDL, is a pathogenic antigen in the context of atherosclerosis 44 . These results suggest that a break in tolerance, rather than the generation of a new antigen, leads to the activation of T H 1 cells, at least in atherosclerotic mice. Furthermore, a restricted set of variable regions in the mouse T cell receptor appears to govern the immune response to native LDL 44 46 . Moreover, one particular biomarker of innate immune activation -C-reactive protein -has proven useful in targeting the use of preventive therapies that can improve outcomes, a gratifying clinical application of basic science advances in understanding inflammation and immunity in atherosclerosis 47 . With respect to the therapeutic implications of the immune responses that occur in atherosclerosis, our 2006 article pointed to a possible direct anti-inflammatory effect of statins as a contributor to their consistent clinical benefit in patients at risk for atherosclerotic cardiovascular complications. In the intervening years, the evidence for such pleiotropic effects of statins has strengthened 48 . Nonetheless, even when receiving high-dose statins and other current standard therapies, many individuals still have an unacceptably high susceptibility to atherosclerotic events. Direct immunomodulatory or anti-inflammatory interventions have now entered clinical evaluation as novel therapeutic approaches to this residual burden of risk. Trials of passive immunization by transfer of specific antibodies to atherosclerosis-related antigens have entered early clinical evaluation, and active immunization strategies are also being developed. Moreover, both a broadly anti-inflammatory intervention (weekly low-dose methotrexate) and a targeted anti-cytokine strategy (neutralization of IL-1β) will soon undergo rigorous evaluation as anti-atherosclerotic approaches in large-scale clinical trials 49 .
Continued work has thus reinforced the importance of inflammation and immunity in atherosclerosis, but as is often the case in scientific endeavours, the data have led us down a path of unanticipated twists and turns. The tantalizing goal of reaping the medical benefits of progress in the fundamental understanding of the double-edged sword of the immune response in atherosclerosis has come a bit closer to reality.
Dendritic cell development -4 years on
Ken Shortman. The interface between different disciplines is often a rewarding zone for research. Shalin Naik and I certainly found this to be the case while working on our Review of steady-state and inflammatory DC development 50 , a research area on the boundary between haematology and immunology. DC development was and remains a complex subject, owing to the multiple specialized subsets of DCs and their developmental plasticity (FIG. 3) . Our attempt to bring some logic and order to the information then available must have been appreciated, given the impact of this Review.
There has of course been substantial progress in the field since our Review in 2007. One positive development is the identification of a human subset equivalent to mouse CD8 + DCs 51 , which gives hope that the developmental pathways of the mouse and human DC systems will prove to be similar. In our Review, we had avoided considering the DCs of the mucosal immune system, because we found the available data confusing. However, the past 4 years have seen a great advancement in our understanding of the similarities between the migratory DCs found in skin, lung and gut tissues 52 . Although many of the concepts presented in the Review remain valid, in some cases the picture has changed. One generalization we made was that many tissues generate their DCs locally from a reservoir of immediate precursors, rather than depending on a continuous input of precursors from the bone marrow. This remains true for the skin DCs known as Langerhans cells. However, the apparent (and we wrote "surprising") independence of spleen DCs from bone marrow input has been shown to be incorrect 53 . Although there is some limited local DC proliferation and maturation in the spleen, maintenance of the spleen DC population does require a continuous input of pre-DCs from the bone marrow.
Our knowledge of the developmental pathway that gives rise to steady-state DCs in the lymphoid tissues and plasmacytoid DCs has recently taken a step forward, with the isolation of a common DC precursor (CDP) 54 (also termed pro-DC 55 ) that exists upstream of the pre-DC. In current consensus models, the precursor further upstream of the CDP is the macrophage-DC precursor (MDP), which was already considered in our Review. The MDP is a neat way of linking the DC and macrophage developmental pathways. However, no clonal data are available to demonstrate that a single restricted precursor of this isolated population gives rise to both macrophages and DCs (steady-state lymphoid tissue-resident DCs and plasmacytoid DCs). We currently dissent from the concept of a common restricted MDP and believe that these cell types develop independently from a myeloid precursor. A clearer picture of the developmental pathways that operate in vivo should soon be obtained by my colleague Shalin Naik, who is applying the molecular 'barcoding' techniques of Ton Schumacher 56 to track DC development.
Mapping DC development at the cellular level by identifying intermediate precursors provides useful signposts along the developmental pathway. However, a full understanding of DC development must now proceed beyond the cellular to the molecular level, with an account of the exogenous factors (such as cytokines) and endogenous factors (such as transcription factors) that govern the differentiation processes involved.
Towards understanding T H 17 cell lineage specification
Chen Dong. Effector CD4 + T cells, which were historically divided between T H 1 and T H 2 subsets, welcomed a new brother, T H 17 cells, 5 years ago (FIG. 4) . The progress in our understanding of the unique extracellular and intracellular regulators of T H 17 cells that occurred at an unprecedented rate was summarized in my 2008 Review, 'T H 17 cells in development: an updated view of their molecular identity and genetic programming' 57 . At a time when T H 17 cell biology had come to some maturity, I attempted to outline the framework of our then knowledge on T H 17 cell development. The Review was well received, to my great satisfaction, and this was due, at least in part, to the interest in T H 17 cells and their relevance to human diseases beyond the immunology community.
Since then, there has been further development in the field and, in my view, several front lines are worth mentioning here.
The first is the identification of new regulators. IL-1 has been found to directly regulate early T H 17 cell differentiation 58 . . It has also become appreciated that T Reg cells may utilize some T H 17 cell-specific molecular pathways to suppress T H 17 cell-mediated immunopathology 63 . The plasticity of T H cell subsets and their genetic and epigenetic cross-regulation is predicted to continue as an important area of T cell biology, but it requires new tools for the genetic reporting of distinct subsets and for 'fate mapping' .
Finally, there are ongoing developments in therapeutic targeting. An IL-12/IL-23p40-specific antibody has been approved for the treatment of psoriasis, and the use of an IL-17-specific antibody has shown promising effects in this and other diseases 64 . Three selective inhibitors of RORγ have been reported [65] [66] [67] , which may be applied to globally inhibit the function of type-17 cytokine producers. New uses for these therapeutic approaches may be explored in the future for other diseases, such as inflammationassociated cancers, in addition to autoinflammatory and autoimmune disorders. This exciting progress in the clinic justifies all the basic research we have been conducting. Nature Reviews | Immunology and ERK2 (which are collectively referred to here as ERK), p38 and nuclear factor-κB (NF-κB) pathways. Activation of these pathways results in the induction of IL-10 expression, in addition to pro-inflammatory cytokines. In myeloid DCs, non-TLR signals through DC-specific ICAM3-grabbing non-integrin (DC-SIGN) and RAF1 can augment TLR2-induced IL-10 production. Furthermore, activation of dectin 1 and the signalling molecules spleen tyrosine kinase (SYK) and ERK results in IL-10 production. In macrophages, a role for nucleotide-binding oligomerization domain 2 (NOD2) signalling in IL-10 induction, in crosstalk with TLR2, has been described. b | Positive and negative feedback loops for IL-10 regulation in macrophages. The p38 and ERK pathways leading to IL-10 expression by macrophages are tightly controlled by interferon-γ (IFNγ) and IL-10 itself. IL-10 feeds back to induce the expression of dual-specificity protein phosphatase 1 (DUSP1), which negatively regulates p38 phosphorylation and thus limits IL-10 production. IL-10 can also positively feed back to upregulate tumour progression locus 2 (TPL2) expression, thus providing a positive amplification loop for its own production. In addition, IFNγ can also interfere with the phosphoinositide 3-kinase (PI3K)-AKT pathway, releasing glycogen synthase kinase 3 (GSK3). As GSK3 normally blocks IL-10 expression by acting on the transcription factors cAMP response element-binding protein (CREB) and activator protein 1 (AP1), IL-10 production is inhibited by IFNγ through its effects on PI3K. IL-10R, IL-10 receptor; MEK, MAPK/ERK1 kinase; MSK, mitogen-and stress-activated protein kinase; RIP2, receptor-interacting protein 2; STAT3, signal transducer and activator of transcription 3; TRAF3, TNFR-associated factor 3. Image is reproduced, with permission, from 
Continued interest in MDSCs
Dmitry Gabrilovich. The ability of some myeloid cells to suppress immune responses has been known for a long time. However, until recently, the biological significance of these cells was not fully appreciated. This situation has changed during the last 8-10 years, with the discovery of the crucial role of myeloid-derived suppressor cells (MDSCs) in controlling immune responses.
In our 2009 Review 68 , we discussed the current knowledge of the nature and biological role of MDSCs. We summarized the evidence indicating that MDSCs are an intrinsic part of the differentiation pathway of myeloid cells and represent a mixed group of cells at different stages of myeloid cell differentiation. These populations are expanded and activated in response to various factors produced in pathological conditions such as tumours, chronic infections, trauma and/ or inflammation. This abnormal activation of MDSCs results in their ability to suppress immune responses in antigen-specific and -nonspecific manners. We proposed that MDSCs represent an important general mechanism for regulating immune responses under different pathological conditions. This mechanism is very rapidly initiated during these conditions and prevents uncontrolled immune reactivity. In tumour-bearing hosts, this mechanism is hijacked by the tumour and is used to inhibit antitumour immune responses. Our Review was highly cited, probably because it coincided with a growing interest in these cells among researchers from different fields and because it presented a cohesive view on this novel group of cells and their potential biological functions.
Since the publication of the Review, the interest in the field of MDSCs has continued to grow, with more than 250 new papers published. We have learned new mechanisms by which MDSCs suppress T cells 69 and NK cells, and promote tumour metastases 70 . New molecular mechanisms that regulate MDSC proliferation have been described in cancer 71, 72 and infections 73 . The liver was found to be a reservoir of MDSCs in tumour-bearing mice 74 . Granulocytic MDSCs and tumour-associated neutrophils have been better characterized in cancer 75, 76 . The functional compartmentalization of MDSCs in peripheral lymphoid organs and the tumour microenvironment has been demonstrated, as well as their ability to differentiate into tumour-associated macrophages 77 . It was demonstrated that human MDSCs could be generated in vitro 71 and, importantly, MDSCs have been shown for the first time to be useful in the context of solid organ transplantation in mice 78 . However, many crucial questions still remain unanswered. Probably the most important address the following key issues: better phenotypic characterization of these cells, especially in humans; better delineation of the nature of these cells vis-à-vis monocytes and neutrophils; identification of specific therapeutic methods to eliminate these cells in cancer; the development of MDSC-based therapy for autoimmune diseases; and the use of these cells in solid organ and stem cell transplantations. We have every reason to believe that the next 10 years will bring new and exciting discoveries associated with these cells.
The regulation of IL-10 production in immune cells
Leona Gabryšová, Ashleigh Howes and Anne O'Garra. IL-10 is an important anti-inflammatory cytokine that prevents inflammatory and autoimmune pathologies by limiting the immune response to pathogens and microbial flora, thereby preventing damage to the host. Many cells of the innate and adaptive immune system produce IL-10; however, the factors that regulate its production in the various cell types are currently unclear. Further complicating the study of IL-10 regulation is the fact that it is induced under feed-forward conditions alongside other cytokines that can modulate its production, giving rise to intricate regulatory networks. This complexity of IL-10 regulation was addressed in our 2010 Review 79 . IL-10 production in innate immune cells (such as macrophages and DCs) and in T cells appears to be regulated by both distinct and common pathways (FIG. 5) . Downstream of TLR activation in macro phages and DCs, the tumour progression locus 2 (TPL2; also known as MAP3K8)-extracellular signalregulated kinase (ERK) pathway is central to the production of IL-10 (REF. 80 ). This is illustrated by the correlation between the levels of ERK activation and IL-10 production by the different innate cell types (reviewed in REF. 79 ). IL-10 production downstream of the pattern recognition receptor dectin 1 (also known as CLEC7A) also requires the ERK pathway 81 . In addition, IL-10 is regulated by other signalling pathways, including the p38 and nuclear factor-κB (NF-κB) pathways (reviewed in REF. 79 ).
Similarly to in macrophages and DCs, ERK signalling is required for IL-10 production by different T H cell subsets -T H 1, T H 2 and T H 17 cells -indicating that ERK is a common regulator of IL-10 in various immune cell types 82 . However, T H cell subset-specific transcription factors have also been implicated in IL-10 regulation. The transcription factor GATA-binding protein 3 (GATA3) -which is essential for the differentiation of T H 2 cells but is not expressed in other T H subsets or in macrophages or DCs -has been shown to remodel the Il10 gene locus 83 . Other transcription factors shown to regulate IL-10 induction -such as signal transducer and activator of transcription 4 (STAT4) in T H 1 cells 82 and MAF 84, 85 -also have the added complication of being involved in T H cell differentiation. The future challenge, therefore, is to decipher the complex IL-10 regulatory networks in different cell types in response to various stimuli, including the downstream signalling pathways and the transcription factor hierarchies that are specifically involved in Il10 gene regulation. Furthermore, the role of epigenetics and post-transcriptional regulatory events (such as mRNA stability) in the regulation of IL-10 are only just beginning to be understood (reviewed in REF. 79 ). Also of importance is the further characterization of the cellular sources of IL-10 and the timing of its production required to modulate an immune response. 
FOXP3
-T H 1 cells are the major source of IL-10 during Toxoplasma gondii infection 88 . 91, 92 . Thus, owing to this immense complexity, the use of traditional biochemical methods together with genome-wide, highthroughput approaches and bioinformatics in in vitro and in vivo systems is the key to gaining a better understanding of IL-10 regulation in different immune cells. This will then facilitate the fine-tuning of immune intervention strategies.
